3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
Here's Why Ensign Group Shares Are Attracting Investors Now
ENSG stock is surging on revenue growth, acquisitions and raised 2025 earnings and sales guidance.
Here's Why Pediatrix Medical Shares Are Attracting Investors Now
MD shares surge on strong earnings, rising revenues, cost cuts and a new $250M buyback plan.
GENEDX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigating GeneDx Holdings Corp. on Behalf of Stockholders and Encourages Investors to Contact the Firm - GeneDx Holdings ( NASDAQ:WGS )
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Lockheed Martin ( LMT ) To Contact Him Directly To Discuss Their Options
PAHC Stock Surges on Q4 Earnings & Revenue Beat, Gross Margin Down
Phibro Animal Health posts strong Q4 earnings and revenues, fueled by Animal Health growth. Meanwhile, the gross margin contracts.
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation ...
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. ( NASDAQ: WGS ) , You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GeneDx Holdings ( NASDAQ:WGS )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp.
Alcon's Q2 Earnings Beat Estimates, Revenues Miss, Stock Plunges
ALC's Q2 earnings top estimates but revenues fall short, sending shares down more than 10% as margins tightened and 2025 sales outlook narrowed.
MDT Stock Falls Despite Q1 Earnings & Revenue Beat, FY26 EPS View Up
Medtronic tops on Q1 earnings and revenues, raises full-year EPS outlook, but shares dip on board changes.
Cathie Wood's 'Apocalypse Squad' Play? Ark Scoops Up $14.2 Million Worth Of Robinhood Stock - ARK Autonomous Technology & Robotics ETF ( BATS:ARKQ ) , ARK Innovation ETF ( BATS:ARKK )
Ark Invest, led by Cathie Wood, executed notable trades on Monday, focusing on Robinhood Markets Inc. HOOD and Deere & Co. DE. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started Interactive BrokersTrade global markets with low costs and pro-level tools at ...
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.
GENEDX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm - GeneDx Holdings ( NASDAQ:WGS )
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Lockheed Martin ( LMT ) To Contact Him Directly To Discuss Their Options
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.
EYE Stock Gains on Q2 Earnings and Revenue Beat, '25 View Up
National Vision tops on Q2 earnings and revenues, boosts 2025 guidance after strong sales and margin expansion.
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up
Veracyte Q2 earnings and revenues beat estimates, fueled by Decipher and Afirma growth, sending shares up over 15%.
Will GENEDX HOLDINGS ( WGS ) Gain on Rising Earnings Estimates?
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract
BRKR's Q2 profit drops sharply, revenues decrease, and weak demand leads to guidance cuts despite cost-saving plans.
TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up
Tandem Diabetes posts record Q2 sales and higher margins, but earnings miss sends shares tumbling 20%.
ROSEN, LEADING TRIAL ATTORNEYS, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
ROSEN, LEADING TRIAL ATTORNEYS, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation ...
TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product launches.
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. ( NASDAQ: WGS ) , You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GeneDx Holdings ( NASDAQ:WGS )
NEW YORK, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp.
Should You Buy GeneDx Holdings Corp. ( WGS ) After Golden Cross?
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
GENEDX ( WGS ) ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm - GeneDx Holdings ( NASDAQ:WGS )
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Lockheed Martin ( LMT ) To Contact Him Directly To Discuss Their Options
Scott+Scott Attorneys at Law LLP Alerts Investors to Its Investigation Into GeneDx Holdings Corp. ( NASDAQ: WGS ) - GeneDx Holdings ( NASDAQ:WGS )
NEW YORK, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Scott+Scott Attorneys at Law LLP ( "Scott+Scott" ) , a shareholder litigation firm, alerts investors that it is investigating whether GeneDx Holdings Corp. ( "GeneDx" or the "Company" ) WGS or certain of its officers and directors issued misleading ...
Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls
TECH tops Q4 EPS estimates and posts solid revenues, but shrinking margins and operating loss drag shares lower.
OraSure ( OSUR ) Q2 Revenue Falls 43%
OraSure Technologies ( NASDAQ:OSUR ) , a diagnostics and sample collection device company, released its second quarter 2025 results on August 5, 2025. The earnings showed that GAAP revenue was $31.2 million, slightly above the $30.36 million GAAP Wall Street estimate.
IDEXX Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
IDXX posts double-digit Q2 revenue growth, beats EPS estimates and lifts the full-year outlook as margins rise sharply.
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down
HOLX posts better-than-expected Q3 results, but margin contraction and regional headwinds pressure investor sentiment.
Why GeneDx Holdings Stock Crushed It Again Today
It continued to ride high on its solid second-quarter performance.
GENEDX ( WGS ) ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm - GeneDx Holdings ( NASDAQ:WGS )
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Lockheed Martin ( LMT ) To Contact Him Directly To Discuss Their Options
Why GeneDx Holdings Stock Blasted 8% Higher Today
There's nothing like a crushing double beat on quarterly results to give some life to a stock.
Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday - Rich Sparkle Holdings ( NASDAQ:ANPA ) , Amkor Tech ( NASDAQ:AMKR )
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of Sanmina Corporation SANM rose sharply during Tuesday's session after the company reported better-than-expected quarterly financial results.
WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View
GeneDx reports strong Q2 results with record revenues and surging profits. A raised 2025 sales outlook fuels a 26% stock jump.
Will SYK's Q2 Earnings Reflect Strong Growth Despite Tariff Overhang?
Stryker's second-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs and tariffs are likely to have continued to hurt margins.
GeneDx Holdings Corp. ( WGS ) Q2 Earnings and Revenues Beat Estimates
GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of +400.00% and +21.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Baxter Q2 Preview: Can Core Segments Deliver Another Solid Quarter?
BAX aims for modest Q2 growth as core segments build on Q1 momentum and margin gains stabilize after recent recovery.
Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?
GEHC leans on Imaging and PDx strength for Q2, but tariff headwinds and margin pressures could test investor confidence.
Why GENEDX HOLDINGS ( WGS ) Could Beat Earnings Estimates Again
GENEDX HOLDINGS (WGS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Exome and Genome Growth Boost WGS' Q2 Earnings?
GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.
IDEXX to Release Q2 Earnings: What's in Store for the Stock?
IDXX eyes a Q2 earnings jump with CAG growth, global pricing gains, and momentum in water and software segments.
ROSEN, A LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS - GeneDx Holdings ( NASDAQ:WGS )
NEW YORK, July 26, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp.
ROSEN, A Top Ranked Law Firm, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
ROSEN, A Top Ranked Law Firm, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation ...
GeneDx CFO Sells More Than Half of His Shares
On July 11, 2025, Kevin Feeley, Chief Financial Officer of GeneDx Holdings ( NASDAQ:WGS ) , reported the sale of 5,278 shares of the company in multiple transactions, reducing his post-transaction holdings to 3,392 shares.How does this transaction compare to the insider's recent activity?This ...
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Bragar Eagel & Squire, P.C Continues Investigations on Behalf of Lineage, Proficient Auto, PetMed, and GeneDx and Encourages Investors to Contact the Firm - Lineage ( NASDAQ:LINE ) , Proficient Auto Logistics ( NASDAQ:PAL )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PetMed ( PETS ) , GeneDx ( WGS ) , Lineage ( LINE ) , or Proficient Auto ( PAL ) To Contact Him Directly To Discuss Their Options
Analysts Estimate Bausch + Lomb ( BLCO ) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?
West Pharmaceutical targets steady Q2 growth as high-value GLP-1 and SmartDose demand drives segment momentum.
